W
Walter M. Stadler
Researcher at University of Chicago
Publications - 513
Citations - 37554
Walter M. Stadler is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 88, co-authored 494 publications receiving 34323 citations. Previous affiliations of Walter M. Stadler include Cleveland Clinic & Northwestern University.
Papers
More filters
Journal ArticleDOI
Sorafenib in advanced clear-cell renal-cell carcinoma.
Bernard Escudier,Tim Eisen,Walter M. Stadler,Cezary Szczylik,Stéphane Oudard,Michael Siebels,Sylvie Negrier,Christine Chevreau,Ewa Solska,Apurva A. Desai,Frederic Rolland,Tomasz Demkow,Thomas E. Hutson,Martin Gore,Scott Freeman,Brian Schwartz,M. Shan,Ronit Simantov,Ronald M. Bukowski +18 more
TL;DR: As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects.
Journal ArticleDOI
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier,Tim Eisen,Walter M. Stadler,Cezary Szczylik,Stéphane Oudard,Michael Staehler,Sylvie Negrier,Christine Chevreau,Apurva A. Desai,Frederic Rolland,Tomasz Demkow,Thomas E. Hutson,Martin Gore,Sibyl Anderson,Gloria Hofilena,M. Shan,Carol Peña,Chetan Lathia,Ronald M. Bukowski +18 more
TL;DR: Although an OS benefit was not seen on a primary intent-to-treat analysis, results of a secondary OS analysis censoring placebo patients demonstrated a survival advantage for those receiving sorafenib, suggesting an important cross-over effect.
Journal ArticleDOI
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
Mark J. Ratain,Tim Eisen,Walter M. Stadler,Keith T. Flaherty,Stan B. Kaye,Gary L. Rosner,Martin Gore,Apurva A. Desai,Amita Patnaik,Henry Q. Xiong,Eric K. Rowinsky,James L. Abbruzzese,Chenghua Xia,Ronit Simantov,Brian Schwartz,Peter O'Dwyer +15 more
TL;DR: Sorafenib has significant disease-stabilizing activity in metastatic renal cell carcinoma and is tolerable with chronic daily therapy.
Journal ArticleDOI
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
Michael B. Atkins,Manuel Hidalgo,Walter M. Stadler,T. Logan,Janice P. Dutcher,Gary R. Hudes,Young Iee Park,Song Heng Liou,Bonnie Marshall,Joseph Boni,Gary Dukart,Matthew L. Sherman +11 more
TL;DR: In patients with advanced RCC, CCI-779 showed antitumor activity and encouraging survival and was generally well tolerated over the three dose levels tested.
Journal ArticleDOI
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher,Michael J. Morris,Walter M. Stadler,Celestia S. Higano,Ethan Basch,Karim Fizazi,Emmanuel S. Antonarakis,Tomasz M. Beer,Michael A. Carducci,Kim N. Chi,Paul G. Corn,Johann S. de Bono,Robert Dreicer,Daniel J. George,Elisabeth I. Heath,Maha Hussain,Wm. Kevin Kelly,Glenn Liu,Christopher J. Logothetis,David M. Nanus,Mark N. Stein,Dana E. Rathkopf,Susan F. Slovin,Charles J. Ryan,Oliver Sartor,Eric J. Small,Matthew R. Smith,Cora N. Sternberg,Mary-Ellen Taplin,George Wilding,Peter S. Nelson,Lawrence H. Schwartz,Susan Halabi,Philip W. Kantoff,Andrew J. Armstrong +34 more
TL;DR: The concept of no longer clinically benefiting is introduced to underscore the distinction between first evidence of progression and the clinical need to terminate or change treatment, and the importance of documenting progression in existing lesions as distinct from the development of new lesions.